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Abstract
Acinetobacter baumannii is one of the opportunistic bacteria firstly related with 
the hospital acquired infection influencing primarily to weakening the patient in the 
ICU. It is sometimes transferred to the patient by transient colonization of hands of 
the workers of healthcare, and persistence on eco-surfaces. Acinetobacter bau-
mannii inhalation aerosolized through endo-tracheal suctioning of the ventilated 
patient is widespread among ventilator-related pneumonia (VAP). It is infections 
mainly associated with ventilator-related pneumonia (VAP), community Acquired 
Pneumonia (CAP), invasive bacterial infections (IBIs) and UTI (urinary tract 
infection). It is one of the prominent uropathogens problematic with antibiotic 
resistance especially carbapenem resistant Acinetobacter baumannii (CRAB). Their 
colonization of urinary tract and establishment of infection may attributed mainly 
to set of virulence factors like: Acinetobactin-assisted iron acquisition system, 
Bap (biofilm-related protein), phospholipase D, Ata (Acinetobacter trimeric 
autotransporter), chaperone-usher type pilus (Csu), OmpA (outer membrane 
protein A), and Plasminogen-binding protein (CipA). The common drugs used for 
treatment Acinetobacter baumannii infections involve polymyxins, glycylcyclines, 
tetracyclines, mono-bactams, fluoroquinolones, aminoglycosides, antipseudomonal 
carbapenems, antipseudomonal cephalosporins, and sulbactam. The rates of MDR 
isolation or also comprehensively the resistant Acinetobacter baumannii are sig-
nificantly increased and so the combination of two or more (colistin, tigecycline, or 
colistin-rifampicin combination therapy) drugs is sometimes used to treat infec-
tions of MDR-AB. As a conclusion the Acinetobacter baumannii engagement in 
urinary tract infections attributed mainly to their adhesins, invasins and intrinsic 
antibiotic resistance.
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1. Introduction
Acinetobacter baumannii is a polymorphic bacterium, rode shaped, gram nega-
tive, immobile, and aerobic. It is an opportunistic bacterium mainly related with 
the hospital acquired disease. It has highly incidence among immune-compromised 
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people, especially those who have suffered from prolonged hospital stay (more 
than 90 days) [1]. A. baumannii bacterium is one of the major states of the 
infections of hospitals that firstly affect the exhausted patients in the ICU, not-
withstanding the prevalence to long-term care facilities and to regular wards is 
becoming larger. It is distinguished by its great determination in environments and 
has a specially ability for enhancing the resistance to every antibiotic [2].
Acinetobacter baumannii usually causes the hospital infections, mostly catheter-
related bacteremia, and aspiration pneumonia, but also can cause infections of 
urinary tract and soft tissue. Community-acquired infections Acinetobacter species 
are progressively recorded. Transfer of Acinetobacter, and sub-sequent diseases are 
expedited by environmental persistence of the microbes, resistance to dehydration 
and avoiding host immunity [3–5].
The characteristics of virulence exhibited by species of Acinetobacter mainly 
arises from avoiding of quick removal by the innate immunological system, actively 
expediting a highly bacterial density which leads to the formation of receptor of 
lipopolysaccharide-Toll-like 4 (TLR4)-assisted sepsis. Polysaccharides of capsule are 
critical virulence agents that enable immune evasion, whereas LPSs lead to the septic 
shock [6]. The newly increase in casualties, greatly related with the infected combat 
soldiers reverting from the conflict districts, and a high increasing in casualties of 
multidrug resistant isolates (MDRs) have increased the emerging opportunistic bac-
terium profile, significantly [7]. MDR-A. baumannii, defined as a strain resistant to 
3 or more groups of antimicrobial agents. They are involving the carbapenem, which 
has emerged as a main cause of healthcare-related infection [8, 9]. The infections of 
A. baumannii are difficult for treating and related with highly, and mortality, and 
staying for a long time at hospitals [10, 11].
2. Acinetobacter spp.
Bacteria of the genus Acinetobacter are ubiquitous, free living, saprophytic 
organisms that can be isolated from soil, water, sewage, and a wide variety of 
foods. They are common components of food spoilage flora. Acinetobacter johnsonii 
and Acinetobacter lwoffi are the species most often isolated from foods, but other 
species, like the opportunistic pathogen Acinetobacter baumannii also can be found 
in spoilage flora [12]. Acinetobacter genus is very variant, consisting of negative 
and positive oxidase, non-pigmented, and gram negative cocco-bacilli. In spite 
of there are more than fifty species of the varied Acinetobacter, most of them 
are non-pathogenic environmental microorganisms. The most common infec-
tions are by A. baumannii, followed by A. lwoffii, and A. calcoaceticus [13, 14]. 
Acinetobacter was found out by Beigerinck, Martinus Willem, a microbiologist 
from Netherlands in 1911. However, for long times, the bacterium Acinetobacter 
had a low-virulence, sensitive to the used common antibiotics, but from 1970, 
resistance of Acinetobacter led to increase and became one of the severe problems, 
particularly in the conditions of hospitals. Currently, the infections by A. bauman-
nii are distinguished to be an important problem and difficult for the controlling 
and treating in critical care conditions [15–17]. A. baumannii lives equally in the 
humid, and dry environments, is resistant to the disinfectant, and extreme drying. 
It enables for forming the biofilm that expedites bacterial binding to the tissue, as 
well as different surfaces of the environment, and rapidly acquires mechanisms of 
the antibiotic resistance. These characteristics are believed to have led to the quick 
endemic prevalence of Acinetobacter baumannii in environments of hospitals and 
several intensive care units worldwide, especially in countries of Europe. Also, 
in 2015, the report of the European Antimicrobial Resistance Control Network 
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referred to that the association of strains of MRD-A. baumannii throughout Europe 
was stably increasing.
However, the highest levels of the drug resistance Acinetobacter baumannii 
were remarked in the states of Baltic particularly in Lithuania and in Southeastern 
and Southern Europe. In 2017, this bacterial species was involved in the general 
priority list of WHO for drug-resistant bacteria for a big need to the development of 
research, and the insistence for novel antimicrobial agents [18]. Acinetobacter spp. 
are normally dwell skin, mucous membranes or the pharynx, and human respira-
tory secretions as normal flora It accountable for a wide variety of local and sys-
temic infections, including pneumonia, septicemia, wound infections and urinary 
tract infections. The main body areas populated by these microorganisms in hospi-
talized patients are the skin, oropharynx, and digestive tract [19–21]. Additionally it 
can survive in dry abiotic environment like medical devices, disposables mattresses, 
pillows and equipment for long periods. It can stay on glass for 20 days and their 
staying on another dry surface may be 4 moths [22].
3. Urinary tract infections
A. baumannii infections involve body systems that with high levels of fluids 
such as urinary and respiratory tract, peritoneal cavity, and are linked to indwelling 
devices [21]. The UTI (Urinary tract infection) has a main public health concern in 
sciences of medicine and represents one of the most commonly infectious diseases 
classified next to infections of the upper respiratory tract. They precipitate to 
nosocomial infections in several hospitals and account approx. 35% of all diseases 
obtained in the hospitals. Unhealthy lacks of proper genital washing and sexual 
intercourse have led to spread UTI. [23]. Genitourinary infections regards third 
important hospital infections proceed by respiratory and surgical wound infections 
A. baumannii responsible for 5-9% of UTIS [24–26].
A. baumannii compile 1-2% of all healthcare-related infections in the USA, 
Europe and Middle East [27]. A. baumannii Catheter associated UTIs (CAUTI) 
is most recently UTIs rerated to biofilm formation among uropathogens. A. bau-
mannii was implicated as uropathogens and 20% of all isolates were isolated from 
patients with UTIs [28]. This organism is usually linked to catheter-associated 
infection or colonization. It is unusual for A. baumannii to cause complicated UTI 
in outpatients. Epidemiologically MDR-AB were widespread worldwide: Europe, 
North America, Argentina, Brazil, China, Taiwan, Hong Kong, Japan, and Korea 
[29–31]. Cross-transmission and diffusion from the hospital environment are more 
likely than endogenous sources to be the source of infecting or colonizing organisms 
in nosocomial infections [32]. A. baumannii very dangerous specially in individuals 
who have recently undergone major surgery, have malignant diseases or burns or 
immuno-suppressed patients such as the elderly, neonates with low birth weights, 
and patients with prolonged illnesses [33].War-associated infections was clearly 
linked to A. baumannii when reported during the Korean War, the Vietnam War, 
and the wars in Iraq and Afghanistan [34, 35]. Biofilm formation were investigated 
among more than 75% of A. baumannii isolates and it can bind to the host epithelial 
cells via set of adhesins like Csu, OmpA and Bap [36–39].
4. Virulence factors
The interaction between cells of the host and pathogens is important in the 
pathogenesis of some bacteria leads to its internalization. Although proving the 
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infections, the bacteria must be colonizing the host. The binding of pathogens to 
cells of the host is enhanced by different molecules expression or structures by 
cells of bacteria. Adhesion depends on the interferences of proteins of the host cell 
surface or soluble proteins with receptors. The proteins act as a bridge between 
cells of the host and bacteria. Adherence of microbes to cells of the host as a first 
step of colonization is an important virulence agent [40, 41]. Few molecular agents 
are needed to the virulence of A. baumannii in human. They involve excessively 
phospholipase D, OmpA (outer membrane protein A), Csu (chaperone usher type 
pilus), Bap (biofilm associated protein), acinetobactin assisted Fe acquisition 
system, and Ata (Acinetobacter trimeric autotransporter), [42]. The role of each of 
them in virulence was listed below:
4.1 Bap (biofilm-associated protein)
In vitro, cells of A. baumannii easily form the biofilm, and the capability of 
nosocomial strains for forming the biofilm on the medical devices as in tissues of 
the host finds a critical agent in the virulence of bacteria. The cells that synthe-
size the biofilms are included in the polymeric conglomerate of polysaccharides 
and proteins. The biofilm resists immune defenses of the host, antibiotics and 
detergents, and antibiotic resistance to bacteria in these habitats can be increased 
to 1000 times [43, 44]. The biofilm finally grows by producing poly-beta (1-6) 
N-acetyl-glucosamine controlled by pgalocus. The extracellular matrix gives 
an adhesion among the cells of bacteria, allowing the synthesis of multilayer 
structures. Also, many surface proteins are included in the process, and show to 
expressively contribute to the binding of the bacterial cells to abiotic or biological 
surfaces. Directly, Bap (biofilm associated protein), a special cell surface protein, 
is included in the formation of the biofilm by Acinetobacter baumannii and plays a 
main role in the processes of infectious bacteria. It is involved in intercellular adhe-
sion within the mature biofilm [45]. Bap (Acinetobacter baumannii biofilm-related 
protein) is necessary to form a mature biofilm on the medically-relevant surfaces, 
involving polystyrene, titanium, and polypropylene, and Bap acts as the surface 
structure included in A. baumannii adherence to normal human neonatal kerati-
nocytes and normal human bronchial epithelial cells. The finding Bap increases 
hydrophobicity of surface of the cell of bacteria [46]. Bap is A giant protein plays 
a great role in the formation of biofilms and adhesion to cells of the host in A. bau-
mannii. Most of the protein is synthesized by arrays of 80 to 110 modules featuring 
Ig-like (immunoglobulin-like) motifs. Bap types includes BLP1, and BLP2 which 
included in the formation of biofilms and assembled in dissimilar A. baumannii 
isolates. However, adhesion patterns and phenotypes of the biofilm of some clinical 
strains appear to be associated with the finding broadspectrum antibiotic resis-
tances. Also, the arrangement of the development, and formation of the biofilms 
diverse like surfaces on which these bacteria persist and components of cells that 
contribute in the multi-step programmed process. The regulatory processes related 
with the synthesis of biofilms involve sensing density of the cells of bacteria, the 
finding various nutrients and concentrations of free cations found for the cells of 
bacteria. Extracellularlly, some of the signals maybe sensed by 2 component regula-
tory systems like Bfm RS. The transcriptional regulatory system activates expres-
sions of usher-chaperone assembly systems accountable to produce pili, needed 
for the synthesis of the biofilms on the polystyrene surfaces, and cell attachment. 
Nevertheless, this system is not required for the formation of biofilms on abiotic 
surfaces when the cells are cultured in the industrial medium. Interestingly, system 
of Bfm RS controls the shape of the cell under certain cultural setting. Biofilm 
tolerance to host immune defenses, disinfectants, and antimicrobials [47, 48].
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4.2 OmpA (Outer membrane protein A)
The main protein of outer membranes, (OmpA), is the most abundant surface 
protein. Also, it is necessary to bind A. baumannii to human alveolar epithelium, 
but it also plays a useful role in the enhancement of biofilms on plastics. Among the 
identified proteins of outer membrane in A. baumannii, AbOmpA acts as a porin, 
which is required for adhesion of eukaryotic cells, and participates to resistance of 
serum and the biofilm formation, partially. The OmpA group is proposed to have a 
variety of functions, involving adhesion to epithelial cells of the host, functions of 
biofilms, and complement resistance [49]. Additionally, overexpression of chromo-
somal efflux systems was received great attention. However, the over-production 
of these systems confers increased MDR to antibacterial factors and induces death 
of cells of the host through nuclear and mitochondrial targeting [50–52]. OmpA 
thought to participate to the antibacteral resistance of A. baumannii during a prob-
able interaction between efflux pump systems and its OmpA-like domain [53].
4.3 Phospholipase D
PL (Phospholipase) is an essential enzyme, necessary for phosphatidylcholine 
metabolism and was studied in a variety spectrum of microbes. About, 3 phospholi-
pase classes (PLC, PLD, and PLA) were identified by the cleavage site. PLA analyzes 
the fatty acid of the glycerol backbone. When PLC cleavage, the phosphorylated 
head groups are released from PLD and phospholipid cleaves off just the head 
group. The releasing the polar head group and the releasing the phosphorylated 
head group can affect the constancy of membranes of the host cells. Additionally, 
phospholipase can interfere with cellular signaling by generating 2nd messengers 
such as phosphatidic acid, which can modify the immune responses of the host [54]. 
It is assumed that many pathogens exploit certain enzymes for enhancement of 
membranes in the coordinated form, thus, these enzymes play an important role as 
virulent agents. An example is PLD (phospholipase D), an enzyme that hydrolyses 
structural phospholipids which results in PA (phosphatidic acid) production, a 2nd 
messenger that acts as an assistor in several cellular processes. Phospholipase as 
a virulence agent was implicated in many bacteria. In vivo, PLD of A. baumannii 
supports pathogenesis and invasion [55, 56]. The disrupting A. baumannii phos-
pholipase D caused reducing capability of organisms to grow in the blood serum, 
decreased pathogenesis and decreasing epithelial cell invasion [57].
4.4 Csu (chaperone-usher type pilus)
The attachment of primary cell can be reasonably assisted by a pili -like 
structure encoded by the position of csu, which is widely spread among clinical 
strains. A. baumannii ability to form the biofilm largely depends on pilus, which 
assists formation and attachment of biofilms. In similar, csu E, is one of the 
members of the system of usher-chaperone. Genes clustered together in the form 
of opera csu, whose products form pili-like bundle structures in these bacteria. 
This gene has confirmed to be a meaningful agent in the formation of A. bauman-
nii biofilm [58, 59].
4.5 Acinetobacter trimeric autotransporter (Ata)
The Ata (Acinetobacter Trimeric automatic transmission adhesive) per-
tains to the trimeric autotransporter adhesin super-family which is meaningful 
virulence agents in several gram negative pathogens. Also, the TAA (Trimeric 
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autotransporter), called as the Vc type secretion system, is declared by several A. 
baumannii isolates, an opportunistic bacteria, answerable for the infections in 
hospitals globally. The TAA, is a modular homotrimeric virulence agent, including 
conserved membrane anchoring domain, the signal peptide, and complex stalk. In 
vivo, mechanisms of the evolutionary underlying the development of this adhesin 
is not clear. The Ata is an useful multi-functional virulence agent in the bacterium 
Acinetobacter baumannii that assists the invasion and the adhesion, participates 
with pathogenicity, and incites apoptosis [60]. It was found that the Ata is acting as 
a multi-functional virulence agent of Acinetobacter baumannii by (1) mediating 
the invasion and adhesion in cells of epithelial and endothelial, (2) leading to the 
programmed cell death in a caspas-dependent manner, (3) leading to the secreting 
IL-6 and IL-8 as proinflammatory cytokines, and (4) in vivo, contributes to the 
virulence. These results forcefully propose that The Ata was uses as useful virulence 
factors for the bacterium Acinetobacter baumannii through the infections in models 
of insect and human [61].
4.6 System of Acinetobactin-assisted iron acquisition
The siderophore is highly converged iron chelators synthesized and applied 
using some bacteria to thrive under the iron-reducing which conditions typi-
cally encountered in hosts and the environment [62]. A. baumannii produces 
up to 3 siderophores namely, baumannoferrin, fimsbactin, and acinetobactin. 
The producing baumannoferrin, and acinetobactin is beggarly conserved among 
clinical strains, whereas the producting fimsbactin is lesser common. Fimsbactins 
are structurally linked to acinetobactin by the finding catecholate, and phenolate 
oxazoline metal binding motifs. Both are derived from nonribosomal peptide 
synthesis lines with similar catalytic domain, identities, and orientations. [63]. The 
system of acetinopactin-assisted iron acquisition was the most distinctive system 
in Acinetobacter baumannii. Acinetobactins, catechol-hydroxamate siderophores, 
and non cyclic derivative of DHBA, that associated with N-hydroxyhistamine, 
and threonine. Acinetobactins are synthesized and used by 3 hypothetical systems 
encoded within the gene clusters of acinetobactin in Acinetobacter baumannii. 
Acinetobactins are manufactured from threonine, hydroxy histamine, and DHBA 
by the encoded proteins by genes in the gene cluster. The mixed kind siderophore, 
which constitutes of hydroxamite groups and catechols groups, shows a significant 
affinity of Fe. Acinetobacter baumannii that is produced acinetobactin is secreted 
system of the siderophore efflux the super-family of ABC [64].
4.7 CipA (plasminogen binding protein)
The CipA (Plasminogen-binding protein) is an external membrane protein, 
links to active forms of the plasmin, and plasminogen, to break down fibrinogen 
and encourage the spread of bacteria. Also, this CipA plasmin breaks down C3b. 
Nevertheless, there is no correlation among CipA plasmin levels, and complement 
resistance so far. Thus, the mechanism by which CipA gives the complement resis-
tance still needs clarification. The CipA disrupts the system of alternative supple-
ments and supports the penetration of layers of endothelium [65].
5. Antibiotic resistance and therapeutics options
A. baumannii remains difficult for treatment that has an important challenge to 
the clinician and cost to the systems of healthcare. Commonly, the used antibiotics 
7
Virulence and Antibiotic Resistance of Acinetobacter baumannii among Urinary Tract Infections
DOI: http://dx.doi.org/10.5772/intechopen.94508
to treat infections of Acinetobacter baumannii involve polymyxins, glycylcyclines, 
tetracyclines, fluoroquinolones, aminoglycosides, mono-bactams, antipseudo-
monal carbapenems, antipseudomonal cephalosporins, and sulbactam. [66]. 
Colistin was widely investigated as a mono-therapy or as a part of the combination 
treatment, but its application is limited because of the nephrotoxicity. Previously, 
infections of Acinetobacter baumannii to CNS (central nervous system) follow-
ing neurosurgery were recorded and treated with relative success by tigecycline, 
colistin, intraventricular or/and intravenous or colistin-rifampicin combination 
thretment [67]. Application of Colistin exhibits an upward tendency because 
of the VAP overseas and emergence of the bacterial infections of MDR [68]. 
Nevertheless, none of tigecycline or polymyxins was excessively agreed for the 
medical uses in China. Actually, using combinations of beta-lactamase inhibitor 
(sulbactam/ampicillin and sulbactam/cefoperazone) or meropenem as the basis 
of the therapy program associated by levofloxacin or etilmicin is repeatedly used 
in therapies of the empiric antibiotics. Recently, broad spectrum antibiotics were 
greatly applied in the clinical practices, whereas the rate Acinetobacter bauman-
nii resistance shows obvious increases [69, 70]. Significantly, the rates resistant 
Acinetobacter baumannii of or even comprehensively MDR isolation are increased 
in clinic. The studies were exhibited that the rate resistance of Acinetobacter 
baumannii to most the tested antibiotics is more than 50%. Thus, the combina-
tion of two or more antibiotics is sometimes used in treatment of the infections of 
MDR-AB [71, 72].
However, due to its widespread use, resistance of AB to carbapenem antibiotics 
quickly increased, in particular among isolates obtained from the ICU. In China, the 
incidence of resistance of carbapenem (CRAB) increased from the percentage 31% 
in 2005 to the percentage 66.7% in 2014. In USA, it increased from the percentage 
20.6% in 2002 to the percentage 49.2% in 2008. Very few drugs are now available to 
treat CRAB (carbapenem resistant AB). It is hypersensitive to just a few drugs, like 
tigecycline and polymyxin, in vitro [73–75].
Currently, the best therapy for the infections of CRAB is illegible. In China, 
tigecycline based combination treatment, polymyxin based combination treat-
ment, and sulbactam based combination treatment are devised to treat MDR Gram 
negative rode bacteria. Nevertheless, these devises are based on small scale retro-
spective researches, lacking comprehensive and systematic clinical study evidence, 
and no large scale clinical randomized controlled trials were achieved to assess 
their activity in the patient with MDR-A. baumannii. Polymyxin is not greatly 
applied in Mainland China because of the toxic side influences of it [76, 77]. Thus, 
currently, tigecycline treatment and sulbactam treatment are the major clinical 
therapies for CRAB. Nevertheless, several controversies surround tigecycline regi-
men to treat infections of A. baumannii bloodstream (BSI). The US Food and Drug 
Administration devised that tigecycline was autonomously related with highly risks 
of mortality and must just be applied in conditions where therapeutic preferences 
were limited. However, tigecycline exerts a suitable therapeutic influence depend-
ing to some researches, whereas many other researches recorded that tigecycline 
increases the mortality of patient [78, 79].
As a member of Gram negative bacteria, A. baumannii equipped with sets of 
resistance mechanisms including: i) structural bacterial shields (Presence of the 
porin channels and efflux mechanisms), ii) enzymatic inactivation of antibiotics 
(oxacillinase (OXA-type), metallo–beta-lactamases (MBLs), iii) alteration of the 
target or cellular functions due to mutations [80–82].
Due to extensive resistance to antibiotics, new strategies were proposed as alter-
native therapy. Antimicrobial peptides (AMPs) are one of the antimicrobial agents 
with high potential to produce new anti-Acinetobacter drugs. Melittin, Histatin-8, 
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Omega76, AM-CATH36, Hymenochirin, and Mastoparan were suitaple AMPs and 
have the highest anti-A. baumannii [83–85].
Pahge or bacteriophage therapy is another alternative therapy for MDRAP. 
Phages are specific to different bacteria, and they bind to receptors on bacterial 
cell walls to inject deoxyribonucleic acid into the cell and ultimately lyse the cell 
in the lytic phase. Lytic bacteriophage therapy may be an opportunity to combat 
the rapidly growing number of MDR bacteria [86]. Lytic phage, the YMC 13/03/
R2096 ABA BP (phage ΒФ-R2096), which specifically causes the lysis of CRAB 
strains [87].
6. Conclusion
As a conclusion the Acinetobacter baumannii engagement in urinary tract 
infections attributed mainly to their adhesins, invasins and intrinsic antibiotic 
resistance.
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